MetLife Investment Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-15,065
| Closed | -$1.54M | – | 3007 |
|
|
2023
Q2 | $1.54M | Buy |
15,065
+620
| +4% | +$58.7K | 0.01% | 1041 |
|
|
2023
Q1 | $1.31M | Sell |
14,445
-526
| -4% | -$30.9K | 0.01% | 1087 |
|
|
2022
Q4 | $569K | Sell |
14,971
-620
| -4% | -$21.3K | ﹤0.01% | 1564 |
|
|
2022
Q3 | $392K | Hold |
15,591
| – | – | ﹤0.01% | 1815 |
|
|
2022
Q2 | $474K | Hold |
15,591
| – | – | ﹤0.01% | 1704 |
|
|
2022
Q1 | $511K | Buy |
15,591
+5,754
| +58% | +$171K | ﹤0.01% | 1764 |
|
|
2021
Q4 | $259K | Hold |
9,837
| – | – | ﹤0.01% | 1891 |
|
|
2021
Q3 | $990K | Hold |
9,837
| – | – | 0.01% | 1120 |
|
|
2021
Q2 | $1.39M | Buy |
+9,837
| New | +$1.11M | 0.01% | 1014 |
|
|
2020
Q2 | – | Sell |
-9,507
| Closed | -$1.37M | – | 2372 |
|
|
2020
Q1 | $1.37M | Hold |
9,507
| – | – | 0.02% | 767 |
|
|
2019
Q4 | $1.94M | Buy |
9,507
+385
| +4% | +$70.2K | 0.02% | 830 |
|
|
2019
Q3 | $732K | Hold |
9,122
| – | – | 0.01% | 1212 |
|
|
2019
Q2 | $861K | Buy |
9,122
+741
| +9% | +$64K | 0.01% | 1181 |
|
|
2019
Q1 | $716K | Hold |
8,381
| – | – | 0.01% | 1236 |
|
|
2018
Q4 | $470K | Hold |
8,381
| – | – | 0.01% | 1402 |
|
|
2018
Q3 | $685K | Buy |
8,381
+649
| +8% | +$45.7K | 0.01% | 1330 |
|
|
2018
Q2 | $270K | Buy |
7,732
+3,255
| +73% | +$99.1K | ﹤0.01% | 1766 |
|
|
2018
Q1 | $92K | Hold |
4,477
| – | – | ﹤0.01% | 2161 |
|
|
2017
Q4 | $127K | Buy |
+4,477
| New | +$125K | ﹤0.01% | 2149 |
|
Other funds holding RETA
MetLife Investment Management's RETA Position: Q3 2023 in Review
MetLife Investment Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 15,065 shares — an estimated $1.54M sold.
MetLife Investment Management first reported a position in RETA in Q4 2017 and held it in 19 quarters. The position peaked at $1.94M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- MetLife Investment Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- MetLife Investment Management sold 15,065 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.54M.
- MetLife Investment Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 19 quarters.
- MetLife Investment Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.94M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.